Richter Gedeon receives FDA filing acceptance for FYLREVY: stock pre-market at EUR 34.90
Published on 10/16/2026 at 08:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFYLREVY filing and trading outlook
- Gedeon Richter announced FDA acceptance of the FYLREVY application on October 14, 2026.
- Richter Gedeon stock traded pre-market at EUR 34.90 at 8:04 a.m. CEST on October 16, 2026.
- The next scheduled stock report is listed for November 10, 2026, while the next round-number level is 0.29 percent away.
Gedeon Richter plc announced on October 14, 2026, that the U.S. Food and Drug Administration had accepted the New Drug Application for FYLREVY for review. The company’s announcement identifies FYLREVY as an oral estrogen therapy based on estetrol. The announcement was published by Gedeon Richter.
Pre-market indication
Richter Gedeon stock was at EUR 34.90 at Lang & Schwarz at 8:04 a.m. CEST on October 16, 2026. The bid was EUR 34.64 and the ask was EUR 35.16. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Richter Gedeon stock.
What matters today
The next scheduled stock report is listed for November 10, 2026. A move to the next round number of EUR 35.00 would be 0.29 percent above the current price. The latest company-specific development is the FDA filing acceptance dated October 14, 2026.
Market context: Market report BUX.
